secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022603
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates
--------------------------------------------------------------------------------

- Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
- Granted NIH SBIR award of $500,000 for influenza A/B replication inhibitor program.
- Q3 2025 R&D expenses $954,000 vs $3.2M in Q3 2024; net loss $2.0M ($0.19 per share) vs $4.9M ($0.49 per share) year-over-year.
- Raised $4.7M in registered direct offering in September 2025 and $1.03M in private placement in October 2025.
- CC-42344 Phase 2a study completed; showed favorable safety, no SAEs; efficacy not reported due to trial conduct issues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/0001493152-25-022603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225022603/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer